Identification and use of growth hormone secretagogue receptor type 1A antagonists

Abstract

Compounds that are ligands for the growth hormone secretagogue receptor type 1A (GHS-R 1A), as well as pharmaceutically acceptable salts of such compounds, are useful for the manufacture of medicaments for the regulation of food intake.

1 . A method of identifying compositions for decreasing food intake comprising testing one or more compounds in an assay that is indicative of whether a compound acts as a growth hormone secretagogue receptor type 1A (GHS-R 1A) antagonist and testing the ability of any compound identified as a GHS-R 1A antagonist to decrease food intake in a subject.  
     
     
         2 . A method of preparing a pharmaceutical composition comprising providing a compound that has been identified as a growth hormone secretagogue receptor type 1A (GHS-R 1A) antagonist and mixing an effective amount thereof with one or more pharmaceutically acceptable carriers or diluents.  
     
     
         3 . The method of  claim 2 , wherein the method further comprises adding an effective amount of a diabetic agent to the composition.  
     
     
         4 . The method of  claim 2 , wherein the method further comprises adding an effective amount of an antiobesity agent or food-intake regulating agent to the composition.  
     
     
         5 . A method of decreasing food intake in a subject comprising administering to the subject an effective amount of a growth hormone secretagogue receptor type 1A (GHS-R 1A) antagonist.  
     
     
         6 . The method of  claim 5 , wherein the method comprises reducing the body mass index (BMI) of the subject by administering to the subject a GHS-R 1A antagonist in an amount effective for decreasing BMI.  
     
     
         7 . The method of  claim 5 , wherein the method comprises treating obesity in the subject by administering to the subject a GHS-R 1A antagonist in an amount effective for treating obesity.  
     
     
         8 . The method of  claim 7 , wherein the GHS-R 1A antagonist is administered with an antiobesity agent or food intake-regulating agent.  
     
     
         9 . The method of  claim 5 , wherein the method comprises treating type II diabetes in the subject by administering to the subject a GHS-R 1A antagonist in an amount effective for treating diabetes.  
     
     
         10 . The method of  claim 9 , wherein the GHS-R 1A antagonist is administered with an antidiabetic agent.  
     
     
         11 . The method of  claim 7 , wherein the subject is a household pet.  
     
     
         12 . The method of  claim 7 , wherein the subject is a human.  
     
     
         13 . The method of  claim 9 , wherein the subject is a household pet.  
     
     
         14 . The method of  claim 9 , wherein the subject is a human.  
     
     
         15 . The method of  claim 6 , wherein the subject is a household pet.  
     
     
         16 . The method of  claim 6 , wherein the subject is a human.  
     
     
         17 . The method of  claim 8 , wherein the subject is a household pet.  
     
     
         18 . The method of  claim 8 , wherein the subject is a human.  
     
     
         19 . The method of  claim 10 , wherein the subject is a household pet.  
     
     
         20 . The method of  claim 10 , wherein the subject is a human.